Frohman Teresa C, Beh Shin C, Kildebeck Eric J, Narayan Ram, Treadaway Katherine, Frohman Elliot M
Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA; Department of BioEngineering, University of Texas at Dallas, 800 West Campbell Road, Richardson, TX 75080, USA.
Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, TX 75390, USA.
Neurol Clin. 2016 Aug;34(3):483-523. doi: 10.1016/j.ncl.2016.05.001.
Multiple sclerosis (MS) is the most common disabling neurologic disease of young adults. There are now 16 US Food and Drug Administration (FDA)-approved disease-modifying therapies for MS as well as a cohort of other agents commonly used in practice when conventional therapies prove inadequate. This article discusses approved FDA therapies as well as commonly used practice-based therapies for MS, as well as those therapies that can be used in patients attempting to become pregnant, or in patients with an established pregnancy, who require concomitant treatment secondary to recalcitrant disease activity.
多发性硬化症（MS）是年轻成年人中最常见的致残性神经系统疾病。目前有16种美国食品药品监督管理局（FDA）批准的用于治疗MS的疾病修正疗法，以及在传统疗法证明不足时在实际应用中常用的其他一类药物。本文讨论了FDA批准的治疗MS的疗法以及基于实际应用的常用疗法，以及那些可用于试图怀孕的患者或已怀孕且因顽固的疾病活动而需要联合治疗的患者的疗法。
